CNA release photos 1
UPDATE - MedCerts Launches Certified Nursing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals
September 23, 2024 11:41 ET | MedCerts
LIVONIA, Mich., Sept. 23, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today by MedCerts, a typing error was left in the headline. It should say "MedCerts Launches Certified Nursing...
CNA release photos 1
MedCerts Launches Certified Cing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals
September 23, 2024 08:00 ET | MedCerts
LIVONIA, Mich., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Offering a vital solution for healthcare providers requiring more trained personnel and patients in need of qualified care, MedCerts today...
logo.png
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
September 23, 2024 08:00 ET | Oryzon Genomics, S.A.
Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12 compared to previous top line data; nominal statistical...
22157.jpg
Lipid Nanoparticles for Gene Therapy Market Research 2024: Gene Therapy Sales are Projected to Exceed $10bn by 2027 - LNPs have Gained Popularity as Carriers for Gene Therapies
September 18, 2024 09:05 ET | Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy - Lipid nanoparticles" report has been added to ResearchAndMarkets.com's offering.This report discusses the developing trend and...
Valneva Submits Labe
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
September 18, 2024 01:00 ET | VALNEVA
  To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...
BB Logo_Tagline_FullColor.png
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
September 17, 2024 07:30 ET | BridgeBio Pharma, Inc.
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial...
ID Logo Medium PNG (Transparent Background).png
InterDigital Wins Two CSI Awards for Best Immersive Video and Video Processing Technology
September 16, 2024 08:30 ET | InterDigital, Inc.
InterDigital awarded CSI Awards for contributions to MPEG immersive standards and Advanced HDR solutions
Picture2.jpg
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
September 16, 2024 08:30 ET | Adaptive Research Inc
BAMF Health and Adaptive Research announced a strategic partnership to increase physician participation and patient enrollment in clinical trials.
Can-Fite BioPharma Logo.jpg
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
September 16, 2024 07:00 ET | Can-Fite BioPharma Ltd.
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology...
Valneva Announces th
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
September 13, 2024 02:30 ET | VALNEVA
Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its...